PHARVARIS NV (PHVS)

NL00150005Y4 - Common Stock

23.5  -0.19 (-0.8%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PHARVARIS NV

NASDAQ:PHVS (3/27/2024, 8:00:01 PM)

23.5

-0.19 (-0.8%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.22B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PHVS Daily chart

Company Profile

Pharvaris NV operates as a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 65 full-time employees. The company went IPO on 2021-02-05. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Company Info

PHARVARIS NV

J.H. Oortweg 21

Leiden ZUID-HOLLAND

CEO: Berndt Modig

Employees: 65

Website: https://pharvaris.com/

PHVS News

News Image10 days ago - Pharvaris N.V.Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
News Image10 days ago - Pharvaris N.V.Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule...

News Image22 days ago - Pharvaris N.V.Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
News Image22 days ago - Pharvaris N.V.Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...

News Image23 days ago - Pharvaris N.V.Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
News Image23 days ago - Pharvaris N.V.Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...

PHVS Twits

Here you can normally see the latest stock twits on PHVS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example